Dirican, A. Et Al. 2014. Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.12 , 4781-4786.

Dirican, A., Varol, U., Kucukzeybek, Y., Alacacioglu, A., Erten, C., Somali, I., ... Can, A.(2014). Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.12, 4781-4786.

Dirican, Ahmet Et Al. "Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?," ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.12, 4781-4786, 2014

Dirican, Ahmet Et Al. "Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?." ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.12, pp.4781-4786, 2014

Dirican, A. Et Al. (2014) . "Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?." ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.12, pp.4781-4786.

@article{article, author={Ahmet Dirican Et Al. }, title={Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?}, journal={ASIAN PACIFIC JOURNAL OF CANCER PREVENTION}, year=2014, pages={4781-4786} }